Cite
Investigators at University of Texas MD Anderson Cancer Center Describe Findings in Antineoplastics (Venetoclax Consolidation In High-risk Cll Treated With Ibrutinib for ≥1 Year Achieves a High Rate of Undetectable Mrd).
MLA
“Investigators at University of Texas MD Anderson Cancer Center Describe Findings in Antineoplastics (Venetoclax Consolidation In High-Risk Cll Treated With Ibrutinib for ≥1 Year Achieves a High Rate of Undetectable Mrd).” Drug Week, Nov. 2023, p. 1200. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edb&AN=173218471&authtype=sso&custid=ns315887.
APA
Investigators at University of Texas MD Anderson Cancer Center Describe Findings in Antineoplastics (Venetoclax Consolidation In High-risk Cll Treated With Ibrutinib for ≥1 Year Achieves a High Rate of Undetectable Mrd). (2023). Drug Week, 1200.
Chicago
“Investigators at University of Texas MD Anderson Cancer Center Describe Findings in Antineoplastics (Venetoclax Consolidation In High-Risk Cll Treated With Ibrutinib for ≥1 Year Achieves a High Rate of Undetectable Mrd).” 2023. Drug Week, November, 1200. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edb&AN=173218471&authtype=sso&custid=ns315887.